Doug Chapnick, BioLoomics CEO
September 19, 2023 06:00 AM EDTUpdated September 22, 03:05 PM
Financing
Startups
R&D

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

Lei Lei Wu

News Reporter

It was 2012, and Doug Chap­nick was fed up with tra­di­tion­al bio­chem­istry re­search.

That kind of think­ing first led him to a De­part­ment of De­fense …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times